File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Expert consensus on the management of chronic lymphocytic leukaemia in Asia

TitleExpert consensus on the management of chronic lymphocytic leukaemia in Asia
Authors
Tse, EKwong, YLGoh, YTBee, PCNg, SCTan, DCaguioa, PNghia, HDumagay, TNorasetthada, LChuncharunee, SRadhakrishnan, VBagal, BAtmakusuma, TDMulansari, NA
KeywordsAsia
Bcl-2 inhibitors
BTK inhibitors
Chronic lymphocytic leukaemia
Treatment
Issue Date16-Feb-2023
PublisherSpringer
Citation
Clinical and Experimental Medicine, 2023, v. 23, n. 6, p. 2895-2907 How to Cite?
DOI: http://dx.doi.org/10.1007/s10238-023-01007-2
Abstract

In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.


Persistent Identifierhttp://hdl.handle.net/10722/338565
ISSN
1591-8890
2023 Impact Factor: 3.2
2023 SCImago Journal Rankings: 1.038
ISI Accession Number ID
WOS:000939816500003

 

DC FieldValueLanguage
dc.contributor.authorTse, E-
dc.contributor.authorKwong, YL-
dc.contributor.authorGoh, YT-
dc.contributor.authorBee, PC-
dc.contributor.authorNg, SC-
dc.contributor.authorTan, D-
dc.contributor.authorCaguioa, P-
dc.contributor.authorNghia, H-
dc.contributor.authorDumagay, T-
dc.contributor.authorNorasetthada, L-
dc.contributor.authorChuncharunee, S-
dc.contributor.authorRadhakrishnan, V-
dc.contributor.authorBagal, B-
dc.contributor.authorAtmakusuma, TD-
dc.contributor.authorMulansari, NA-
dc.date.accessioned2024-03-11T10:29:51Z-
dc.date.available2024-03-11T10:29:51Z-
dc.date.issued2023-02-16-
dc.identifier.citationClinical and Experimental Medicine, 2023, v. 23, n. 6, p. 2895-2907-
dc.identifier.issn1591-8890-
dc.identifier.urihttp://hdl.handle.net/10722/338565-
dc.description.abstract<p>In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.</p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofClinical and Experimental Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAsia-
dc.subjectBcl-2 inhibitors-
dc.subjectBTK inhibitors-
dc.subjectChronic lymphocytic leukaemia-
dc.subjectTreatment-
dc.titleExpert consensus on the management of chronic lymphocytic leukaemia in Asia-
dc.typeArticle-
dc.identifier.doi10.1007/s10238-023-01007-2-
dc.identifier.scopuseid_2-s2.0-85148217301-
dc.identifier.volume23-
dc.identifier.issue6-
dc.identifier.spage2895-
dc.identifier.epage2907-
dc.identifier.eissn1591-9528-
dc.identifier.isiWOS:000939816500003-
dc.identifier.issnl1591-8890-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats